AXSOME THERAPEUTICS INC. - COMMON STOCK

Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

08 май 2023 07:00:16 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference

03 май 2023 07:00:50 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month

01 май 2023 07:00:31 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting

21 апр 2023 07:00:34 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

14 апр 2023 07:00:49 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report First Quarter 2023 Financial Results on May 8

13 апр 2023 07:00:34 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at Cowen’s 43rd Annual Health Care Conference

01 мар 2023 07:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

27 фев 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Enters into License Agreement with Pharmanovia to Expand Commercialization and Further Develop Sunosi® (solriamfetol) in Europe

22 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the SVB Securities Global Biopharma Conference

07 фев 2023 07:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on February 27

31 янв 2023 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Presents New Data from the EVOLVE Open-Label Trial Demonstrating Effects of AUVELITY® on Cognitive and Physical Functioning in Patients with Major Depressive Disorder at the American College of Neuropsychopharmacology (ACNP) 2022 Annual Meeting

07 дек 2022 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces AXS-05 Achieves Primary Endpoint in the ACCORD Phase 3 Trial in Alzheimer’s Disease Agitation

28 ноя 2022 06:35:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the 5th Annual Evercore ISI HealthCONx Conference

23 ноя 2022 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Present at the Guggenheim 4th Annual Immunology and Neurology Conference

09 ноя 2022 07:00:02 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update

07 ноя 2022 07:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Ring the NASDAQ Stock Market Opening Bell Today

27 окт 2022 07:00:01 Источник Nasdaq GlobeNewswire

Axsome Therapeutics to Report Third Quarter 2022 Financial Results on November 7, 2022

21 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Announces Availability of AUVELITY™, the First and Only Oral NMDA Receptor Antagonist for the Treatment of Major Depressive Disorder in Adults

20 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire

Axsome Therapeutics Voices its Commitment to Mental Health on World Mental Health Day 2022

10 окт 2022 07:00:00 Источник Nasdaq GlobeNewswire